ArticleJHLT open2026
Biomarkers of standard criteria and marginal donor lungs during ex vivo lung perfusion: A comparative study.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances in consistency and variability inJournal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ex vivo lung perfusion (EVLP) is a well-established method for assessing and reconditioning donor lungs before lung transplantation (LTx). Remarkably, clinical outcomes between standard criteria and marginal donor lungs after EVLP are similar despite differences in lung quality. Therefore, we explored several biomarkers during EVLP in this study. Novel findings could guide future interventions to enhance lung quality and expand the donor pool. Methods: EVLP was performed for ≥180 min with 18 standard criteria (logistical) and 15 marginal donor lungs. The biomarkers were measured in the perfusate after 90 and 180 min: d-dimer, Prothrombin Fragment 1+2 (F1+2), Plasminogen Activator Inhibitor-1 (PAI-1), urokinase Plasminogen Activator Receptor (uPAR), IL-1β, IL-6, IL-8, TNF-α, syndecan-1, hyaluronan and Vascular Cell Adhesion Molecule-1 (VCAM-1). Results: In the logistical and marginal group, 16/18 and 12/15 were transplanted, respectively. All biomarkers increased significantly during EVLP. Remarkably, d-dimer, F1+2, uPAR, IL-6, IL-8, syndecan-1, hyaluronan, and VCAM-1 were significantly higher in the marginal group. Declined donor lungs had significantly higher levels of syndecan-1 and hyaluronan than all transplanted donor lungs. Lung function during EVLP and primary graft dysfunction (PGD) were similar between the transplanted standard and marginal lungs. No significant correlations with PGD were observed. Conclusion: Marginal donor lungs sustained more injury as reflected in higher levels of fibrin degradation, inflammation, glycocalyx shedding, and endothelial activation. In addition, declined donor lungs exhibited significantly higher glycocalyx shedding. Therefore, both logistical and marginal donor lungs could potentially benefit from thrombolysis, inflammation-reducing therapy, and endothelial preservation during EVLP to enhance lung quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.